Dabrafenib monotherapy alone or in combination with trametinib (a MEK inhibitor) has demonstrated clinical efficacy and manageable toxicity in patients with relapsed/refractory BRAF V600E–mutant pediatric LCH, with most responses ongoing.8, 9. Here, BRAF is linked to Langerhans cell histiocytosis.